1. Home
  2. MIRM vs CNL Comparison

MIRM vs CNL Comparison

Compare MIRM & CNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CNL
  • Stock Information
  • Founded
  • MIRM 2018
  • CNL 2018
  • Country
  • MIRM United States
  • CNL Canada
  • Employees
  • MIRM N/A
  • CNL N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CNL
  • Sector
  • MIRM Health Care
  • CNL
  • Exchange
  • MIRM Nasdaq
  • CNL NYSE
  • Market Cap
  • MIRM 1.9B
  • CNL 871.3M
  • IPO Year
  • MIRM 2019
  • CNL N/A
  • Fundamental
  • Price
  • MIRM $39.43
  • CNL $10.57
  • Analyst Decision
  • MIRM Strong Buy
  • CNL Strong Buy
  • Analyst Count
  • MIRM 11
  • CNL 1
  • Target Price
  • MIRM $58.55
  • CNL $8.00
  • AVG Volume (30 Days)
  • MIRM 437.5K
  • CNL 121.0K
  • Earning Date
  • MIRM 05-07-2025
  • CNL 01-01-0001
  • Dividend Yield
  • MIRM N/A
  • CNL N/A
  • EPS Growth
  • MIRM N/A
  • CNL N/A
  • EPS
  • MIRM N/A
  • CNL N/A
  • Revenue
  • MIRM $336,888,000.00
  • CNL N/A
  • Revenue This Year
  • MIRM $29.51
  • CNL N/A
  • Revenue Next Year
  • MIRM $20.27
  • CNL N/A
  • P/E Ratio
  • MIRM N/A
  • CNL N/A
  • Revenue Growth
  • MIRM 80.76
  • CNL N/A
  • 52 Week Low
  • MIRM $23.14
  • CNL $2.43
  • 52 Week High
  • MIRM $54.23
  • CNL $11.61
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 38.25
  • CNL N/A
  • Support Level
  • MIRM $38.22
  • CNL N/A
  • Resistance Level
  • MIRM $39.87
  • CNL N/A
  • Average True Range (ATR)
  • MIRM 2.41
  • CNL 0.00
  • MACD
  • MIRM -0.16
  • CNL 0.00
  • Stochastic Oscillator
  • MIRM 29.04
  • CNL 0.00

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CNL COLLECTIVE MINING LTD

Collective Mining Ltd is an exploration and development company focused on identifying and exploring prospective mineral projects in South America. The company currently has interest in two projects located in Colombia, namely, Guayabales and San Antonio. The company is responsible for discovering, permitting, and constructing the gold mine in Colombia. The company is rapidly advancing exploration on large-scale copper-gold-molybdenum porphyry targets in the mining-friendly department of Caldas in Colombia. Drilling is underway at the Guayabales project which is strategically located contiguous to the Marmato deposit, with initial assay results ongoing.

Share on Social Networks: